Amgen Licenses Rights To Multiple Myeloma Drug
socalTECH
SEPTEMBER 1, 2016
The compound is currently in Phase I studies. The two said the drug was originally licensed to Boehringer Ingelheim by Micromet, before Amgen acquired Micromet in 2012. Financial details of the deal were not announced. READ MORE>>.
Let's personalize your content